CAS 2310299-91-1: Gefapixant citrate

Description:Gefapixant citrate is a chemical compound primarily recognized for its role as a selective P2X3 receptor antagonist, which is being investigated for its potential therapeutic applications in treating chronic cough and other related conditions. It is characterized by its ability to inhibit the activity of the P2X3 receptor, a receptor implicated in the sensation of pain and cough reflex. The citrate salt form enhances its solubility and stability, making it suitable for pharmaceutical formulations. Gefapixant citrate is typically administered in oral dosage forms and has undergone various clinical trials to evaluate its efficacy and safety profile. Its mechanism of action involves blocking the ATP-gated ion channel, which is crucial for the transmission of sensory signals related to cough. As with many investigational drugs, ongoing research continues to elucidate its pharmacokinetics, optimal dosing regimens, and potential side effects. Overall, gefapixant citrate represents a promising advancement in the management of chronic cough, with the potential to improve the quality of life for affected individuals.